×

Teva settles US states’ drug price-fixing case

By Thomson Reuters Nov 16, 2026 | 10:32 AM

Nov 16 (Reuters) – Teva Pharmaceutical Industries has settled long-running litigation by most US states accusing the drugmaker and dozens of other ​defendants of conspiring to fix prices on ‌dozens of generic drugs.

• Chief Judge Michael Shea of the federal court in Hartford, Connecticut, put the case on hold on Monday after both sides reached an ‌agreement ​in principle to settle, court ⁠records show. Settlement terms ⁠were not disclosed. The case was brought by 45 US states, Washington, DC and two US territories.

• Teva did not immediately respond to ​requests for comment. The office of Connecticut Attorney General William Tong, whose state leads ⁠the litigation, did not immediately ⁠respond to similar requests.

• The states ​accused Teva and other defendants of having in ​2012 “embarked on one of the most egregious and ‌damaging price-fixing conspiracies in the history of the United States,” in which they allegedly agreed to maintain their “fair share” of each generic drug ⁠market while significantly raising prices on as many drugs as possible.

• Prices skyrocketed in 2013 and 2014, the ⁠states said. ‌Teva significantly raised prices on approximately ⁠112 different generic drugs, and colluded ​with “high ‌quality” competitors to raise prices on ​at least ⁠86 of them, sometimes by more than 1,000%, the states added.

• Shea oversees two other antitrust lawsuits by state attorneys general related to generic drugs.

(Reporting by Jonathan Stempel in New York; Editing by ​Chizu Nomiyama )